BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 15297061)

  • 1. Intravaginal immunization with viral subunit protein plus CpG oligodeoxynucleotides induces protective immunity against HSV-2.
    Kwant A; Rosenthal KL
    Vaccine; 2004 Aug; 22(23-24):3098-104. PubMed ID: 15297061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract.
    Gallichan WS; Woolstencroft RN; Guarasci T; McCluskie MJ; Davis HL; Rosenthal KL
    J Immunol; 2001 Mar; 166(5):3451-7. PubMed ID: 11207303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parameters of CpG oligodeoxynucleotide-induced protection against intravaginal HSV-2 challenge.
    Sajic D; Ashkar AA; Patrick AJ; McCluskie MJ; Davis HL; Levine KL; Holl R; Rosenthal KL
    J Med Virol; 2003 Dec; 71(4):561-8. PubMed ID: 14556270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the estrous cycle on local humoral immune responses and protection of intranasally immunized female mice against herpes simplex virus type 2 infection in the genital tract.
    Gallichan WS; Rosenthal KL
    Virology; 1996 Oct; 224(2):487-97. PubMed ID: 8874509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rectal immunization generates protective immunity in the female genital tract against herpes simplex virus type 2 infection: relative importance of myeloid differentiation factor 88.
    Tengvall S; O'Hagan D; Harandi AM
    Antiviral Res; 2008 Jun; 78(3):202-14. PubMed ID: 18276020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mucosal immunization with inactivated human immunodeficiency virus plus CpG oligodeoxynucleotides induces genital immune responses and protection against intravaginal challenge.
    Dumais N; Patrick A; Moss RB; Davis HL; Rosenthal KL
    J Infect Dis; 2002 Oct; 186(8):1098-105. PubMed ID: 12355360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD8+ T-cell-mediated cross-clade protection in the genital tract following intranasal immunization with inactivated human immunodeficiency virus antigen plus CpG oligodeoxynucleotides.
    Jiang JQ; Patrick A; Moss RB; Rosenthal KL
    J Virol; 2005 Jan; 79(1):393-400. PubMed ID: 15596832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NK and NKT cell-independent contribution of interleukin-15 to innate protection against mucosal viral infection.
    Gill N; Rosenthal KL; Ashkar AA
    J Virol; 2005 Apr; 79(7):4470-8. PubMed ID: 15767447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nasal and skin delivery of IC31(®)-adjuvanted recombinant HSV-2 gD protein confers protection against genital herpes.
    Wizel B; Persson J; Thörn K; Nagy E; Harandi AM
    Vaccine; 2012 Jun; 30(29):4361-8. PubMed ID: 22682292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estradiol limits viral replication following intravaginal immunization leading to diminished mucosal IgG response and non-sterile protection against genital herpes challenge.
    Gillgrass A; Chege D; Bhavanam S; Kaushic C
    Am J Reprod Immunol; 2010 Apr; 63(4):299-309. PubMed ID: 20070285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The mucosal adjuvant effect of alpha-galactosylceramide for induction of protective immunity to sexually transmitted viral infection.
    Lindqvist M; Persson J; Thörn K; Harandi AM
    J Immunol; 2009 May; 182(10):6435-43. PubMed ID: 19414797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intranasal and subcutaneous immunization under the effect of estradiol leads to better protection against genital HSV-2 challenge compared to progesterone.
    Bhavanam S; Snider DP; Kaushic C
    Vaccine; 2008 Nov; 26(48):6165-72. PubMed ID: 18804503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of genital T cell responses to herpes simplex virus type 2 resulting from immunization of the nasal mucosa.
    Milligan GN; Dudley-McClain KL; Chu CF; Young CG
    Virology; 2004 Jan; 318(2):507-15. PubMed ID: 14972519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protection against genital herpes infection in mice immunized under different hormonal conditions correlates with induction of vagina-associated lymphoid tissue.
    Gillgrass AE; Tang VA; Towarnicki KM; Rosenthal KL; Kaushic C
    J Virol; 2005 Mar; 79(5):3117-26. PubMed ID: 15709031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Importance of myeloid differentiation factor 88 in innate and acquired immune protection against genital herpes infection in mice.
    Tengvall S; Harandi AM
    J Reprod Immunol; 2008 Jun; 78(1):49-57. PubMed ID: 17945349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of innate immunity against herpes simplex virus type 2 infection via local delivery of Toll-like receptor ligands correlates with beta interferon production.
    Gill N; Deacon PM; Lichty B; Mossman KL; Ashkar AA
    J Virol; 2006 Oct; 80(20):9943-50. PubMed ID: 17005672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CpG oligodeoxynucleotide augments HSV-2 glycoprotein D DNA vaccine efficacy to generate T helper 1 response and subsequent protection against primary genital herpes infection in mice.
    Tengvall S; Josefsson A; Holmgren J; Harandi AM
    J Reprod Immunol; 2005 Dec; 68(1-2):53-69. PubMed ID: 16229896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intranasal immunization with a proteoliposome-derived cochleate containing recombinant gD protein confers protective immunity against genital herpes in mice.
    Del Campo J; Lindqvist M; Cuello M; Bäckström M; Cabrerra O; Persson J; Perez O; Harandi AM
    Vaccine; 2010 Feb; 28(5):1193-200. PubMed ID: 19945418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunization with HSV-2 gB-CCL19 Fusion Constructs Protects Mice against Lethal Vaginal Challenge.
    Yan Y; Hu K; Deng X; Guan X; Luo S; Tong L; Du T; Fu M; Zhang M; Liu Y; Hu Q
    J Immunol; 2015 Jul; 195(1):329-38. PubMed ID: 25994965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topical herpes simplex virus 2 (HSV-2) vaccination with human papillomavirus vectors expressing gB/gD ectodomains induces genital-tissue-resident memory CD8+ T cells and reduces genital disease and viral shedding after HSV-2 challenge.
    Çuburu N; Wang K; Goodman KN; Pang YY; Thompson CD; Lowy DR; Cohen JI; Schiller JT
    J Virol; 2015 Jan; 89(1):83-96. PubMed ID: 25320297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.